Business
Novocure Highlights Use of Tumor Treating Fields Therapy in Treatment of Non-Small Cell Lung Cancer at 2023 World Conference on Lung Cancer
Presentations include new post-hoc analysis of data from phase 3 LUNAR trial in metastatic non-small cell lung cancer ROOT, Switzerland--(BUSINESS WIRE)--
About this update from Novocure Limited
[{"type":"text","content":"\nPresentations include new post-hoc analysis of data from phase 3 LUNAR trial in metastatic non-small cell lung cancer\n\n\n ROOT, Switzerland--(BUSINESS WIRE)--\nNovocure (NASDAQ: NVCR) today announced its participation in the upcoming International Association for the Study of Lung Cancer (IASLC) 2023 World Conference on Lung Cancer (WCLC) from September 9 – 13, 2023 in Singapore. Novocure will take part in presentations and symposia throughout the event and will exhibit several posters exploring the use of Tumor Treating Fields (TTFields) therapy in the treatment of lung cancer, including a new post-hoc analysis of data from its LUNAR trial in metastatic non-small cell lung cancer.\n\n\nThe LUNAR trial was designed to evaluate the use of TTFields therapy together with standard systemic therapies for the treatment of metastatic non-small cell lung cancer, following progression on or after platinum-based therapy. The trial met its primary endpoint, demonstrating a statistically significant and clinically meaningful extension in overall survival (OS) for patients treated with TTFields and standard systemic therapies, as well as a pronounced extension in OS for patients randomized to receive physician’s choice immune checkpoint inhibitor (ICI) together with TTFields.\n\n\nIn a new post-hoc analysis of data from the LUNAR trial, researchers reviewed survival patterns of patients with known Tumor Proportion Scores (TPS) randomized to receive ICI together with or without TTFields. Among patients with TPS >1%, median OS for patients treated with TTFields therapy and ICI (n=22) was 23.6 months compared to 10.5 months for patients treated with ICI alone (n=26; HR: 0.49, P=0.045).\n\n\nFurther analysis shows evidence of a relationship between increasing PD-L1 expression and improved survival outcomes. In patients with TPS 1–49%, median OS was 19.0 months for patients treated with TTFields therapy and ICI (n=17), compared to 9.7 months for patients treated with ICI alone (n=18; HR: 0.55, P=0.14). In patients with TPS >50%, median OS was not reached for patients treated with TTFields therapy and ICI (n=5) compared to 30.0 months for patients treated with ICI alone (n=8; HR: 0.17, P=0.07).\n\n\nThese data will be presented on September 12, 2023 at 2:30 p.m. UTC+8 by primary investigator Ticiana Leal, M.D., a researcher and medical oncolog...